NETTER-2
¹⁷⁷Lu-DOTATATE moved to the front line, first-line PRRT for higher-grade GEP-NETs
Quick Answer
NETTER-2 (Singh et al., Lancet 2024) was the phase 3 randomized trial that established ¹⁷⁷Lu-DOTATATE as a first-line therapy for newly diagnosed, higher-grade (grade 2 and grade 3) somatostatin-receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Added to standard-dose octreotide, PRRT more than doubled progression-free survival versus high-dose octreotide alone — extending PRRT beyond the progressive low-grade midgut population of NETTER-1 into front-line, higher-grade disease.
The trial
Design: phase 3, open-label, randomized trial of 226 patients with newly diagnosed, advanced grade 2–3 (Ki-67 ≈ 10–55%) SSTR-positive GEP-NETs. Randomized 2:1 to four cycles of ¹⁷⁷Lu-DOTATATE plus standard-dose octreotide versus high-dose (long-acting 60 mg) octreotide alone. Primary endpoint: progression-free survival.
Key result
PRRT markedly improved median PFS (≈22.8 vs 8.5 months; HR ≈ 0.28) with a higher objective response rate (≈43% vs 9%). Benefit was seen across grade 2 and grade 3 strata. Safety was consistent with the known PRRT profile — manageable, with low rates of serious hematologic toxicity over the trial period.
Why it mattered
NETTER-2 is the first randomized evidence supporting PRRT as an up-front (first-line) option in higher-grade SSTR-positive GEP-NETs, rather than reserving it for progression after somatostatin analogues. It broadened the eligible population from NETTER-1's progressive low-grade midgut tumors to treatment-naïve grade 2–3 disease, reshaping first-line sequencing when SSTR imaging confirms target expression.
Context & caveats
Eligibility required SSTR-positive disease (adequate uptake on ⁶⁸Ga-DOTATATE/⁶⁸Ga-DOTATOC PET), so patients with discordant, poorly differentiated, or FDG-avid/SSTR-negative tumors were not the target population. The comparator was high-dose octreotide rather than chemotherapy, and follow-up for overall survival continues to mature.
Self-Check
Q1. What did NETTER-2 establish?
Answer: That ¹⁷⁷Lu-DOTATATE is effective first-line in newly diagnosed higher-grade (grade 2–3) SSTR-positive GEP-NETs — more than doubling PFS versus high-dose octreotide alone.
Q2. How does NETTER-2 differ from NETTER-1?
Answer: NETTER-1 treated progressive low-grade midgut NETs after somatostatin-analogue failure; NETTER-2 moved PRRT to first-line in treatment-naïve grade 2–3 GEP-NETs.
Q3. What were the key efficacy numbers?
Answer: Median PFS ≈ 22.8 vs 8.5 months (HR ≈ 0.28) and objective response ≈ 43% vs 9%.
Q4. What is the essential eligibility requirement?
Answer: SSTR-positive disease confirmed on ⁶⁸Ga-DOTATATE/DOTATOC PET — the imaging target must be present for PRRT to be appropriate.
Key References
- Singh S, et al. [¹⁷⁷Lu]Lu-DOTATATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 2024;403:2807–2817. doi:10.1016/S0140-6736(24)00701-3
Evidence & sources
https://nuc.med/netter-2-trial/ Report an issue